orivan cancer
Conditions
Interventions
Case series:Nil
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Aged >=18 years old; (2) Epithelial ovarian cancer was confirmed; (3) According to the evaluation of the researchers, they need to accept and tolerate the conventional first-line chemotherapy, or they need to accept the second-line or multi line chemotherapy after the failure of the first-line treatment; (4) There was at least one measurable tumor lesion in accordance with recist1.1; (5) The expected survival time was more than 3 months; (6) Willing to participate in this clinical study, able to cooperate with the researcher to carry out the study, and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) It is known that there are contraindications for the upcoming first-line chemotherapy or second-line and multi-line chemotherapy plans; (2) The patients' lesions could not be obtained for primary cell culture in vitro; (3) The toxicity of previous anti-cancer treatment has not been recovered, or has not been completely recovered from previous operations; The results of drug sensitivity test were not obtained due to failure of culture; (4) The baseline had brain metastasis; (5) The cancer was not cured; The second primary cancer patients were pregnant and lactating women, and those who were preparing for pregnancy in the near future; (6) The following active infectious diseases, including tuberculosis active period, hepatitis three Yang patients, known human immunodeficiency virus (HIV) infection. Those who are unable to cooperate or unwilling to cooperate with each other due to neurological or mental disorders; (7) The past history showed that there were serious complications: severe chronic obstructive pulmonary disease with hypoxemia; Uncontrolled hypertension, cerebrovascular accident / stroke, myocardial infarction, unstable angina, thromboembolism, chronic congestive heart failure, or serious arrhythmias requiring drug treatment; The history of severe hepatitis and liver disease; Renal syndrome and renal insufficiency; History of active ulcer, abdominal wall fistula, gastrointestinal perforation, or intraperitoneal abscess; Uncontrolled diabetes mellitus; Uncontrolled epilepsy requiring long-term anticonvulsion treatment. (8) Appropriate organ function, excluded from group if: Absolute neutrophil count (ANC) in the laboratory examination results within 1 week before randomization =1.0g/24h in 24 hours; Partial prothrombin time (APTT) and prothrombin time (PT) exceed 1.5 ULN (subject to the normal value of clinical trial and Research Center); (9) The skin wound, the operation site, the wound site, the serious ulcer or fracture of the mucosa did not heal completely; (10) The non gynaecological surgery with the length of more than 4 hours was accepted within 60 days before the randomization; (11) The pregnancy was positive before the first drug use in pregnant or lactation women or women with pregnancy possibility; (12) The patient or sexual partner who has fertility but is not willing to accept contraceptive measures is not willing to accept contraceptive measures; (13) The researchers think that the subjects are not suitable for the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ca125;HE4; | — |
Countries
China
Contacts
Public ContactZhou Ying
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed